Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

Hepatology Research

Volumn 35, Issue 3, 2006, Pages 185-189

  Hiramatsu, Naoki ^a   Oze, Tsugiko ^a   Tsuda, Natsuko ^a   Kurashige, Nao ^a   Koga, Keisuke ^a   Toyama, Takashi ^a   Yasumaru, Masakazu ^a   Kanto, Tatsuya ^a   Takehara, Tetsuo ^a   Kasahara, Akinori ^a   Kato, Michio ^b   Yoshihara, Harumasa ^c   Katayama, Kazuhiro ^d   Hijioka, Taizo ^e   Hagiwara, Hideki ^f   Kubota, Shinji ^g   Oshita, Masahide ^h   Haruna, Yoshimichi ⁱ   Mita, Eiji ^l   Suzuki, Kunio ^j   Ishibashi, Kazunobu ^k   Hayashi, Norio ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^e MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^f Higashiosaka City General Hospital   (Japan)

^g Japan Labour Health and Welfare Organization   (Japan)

^h OSAKA POLICE HOSPITAL   (Japan)

ⁱ OSAKA GENERAL MEDICAL CENTER   (Japan)

^j Saiseikai Senri Hospital   (Japan)

^k Kaizuka City Hospital   (Japan)

^l NONE

more..

Author keywords

Aged patient; Chronic hepatitis C; Interferon and ribavirin combination therapy

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUTROPENIA; PRIORITY JOURNAL; SEROTYPE; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 33745713940     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2006.03.008     Document Type: Article

References (24)

1. Lauer G., and Walker B.D. Hepatitis C virus infection. N Engl J Med 345 (2001) 41-52
2. Poynard T., Bedossa P., Opolon P., et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
3. Hamada H., Yatsuhashi H., Yano K., et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 95 2 (2002) 331-339
4. Tanaka H., and Tsukuma H. Characteristics of Japanese patients with liver cancer-epidemiological study based on comparison between male and female patients. Hepatology Res 24 (2002) S11-S20
5. Yoshizawa H. Trends of hepatitis virus carriers. Hepatology Res 24 (2002) S28-S39
6. Shiratori Y., Imazeki F., Moriyama M., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 (2000) 517-524
7. Hiramatsu N., Hayashi N., Kasahara A., et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22 (1995) 135-142
8. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of chronic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131 (1999) 174-181
9. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27 (1998) 1394-1402
10. Ikeda K., Saitoh S., Arase Y., et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 19 (1999) 1124-1130
11. Kasahara A., Tanaka H., Okanoue T., et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 11 2 (2004) 148-156
12. Yoshida H., Arakawa Y., Sata M., et al. Interferon therapy prolonged life expectancy among chronic hepatits C patients. Gastroenterology 123 (2002) 4483-4491
13. Imai Y., Kasahara A., Tanaka H., et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 39 (2004) 1069-1077
14. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alpha 2b alone or combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 229 (1998) 1485-1492
15. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
16. Hiramatsu N., Kasahara A., Nakanishi F., et al. The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan. Hepatol Res 29 3 (2004) 142-147
17. Bodenheimer H.C., Lindsay K.L., Davis G.L., et al. Tolerance and efficacy of oral ribavirin treatment of chronic heoatitis C: A multicenter trial. Hepatology 26 (1997) 437-477
18. Okanoue T., Sakamoto S., Itoh Y., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25 (1996) 283-291
19. Yuki N., Hayashi N., Kasahara A., et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 22 (1995) 457-463
20. Lau Y.N., Davis G., Kniffen J., et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341 (1993) 1501-1504
21. Shiratori Y., Kato N., Yokosuka O., et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 113 (1997) 558-566
22. Tanaka T., Tsukiyama-Kohara K., Yamaguchi K., et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19 (1994) 1347-1353
23. Lindahl K., Schvarcz R., Bruchfeld A., et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia. J Viral Hepatitis 11 (2004) 84-87
24. Maeda Y., Kiribayashi Y., Moriya T., et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther. Drug Monit 26 (2004) 9-15